Theranostics is a groundbreaking topic that's reshaping how we diagnose and treat cancer. It's a cutting-edge
approach in cancer care, combining diagnosing and treating cancer using the same molecular tools. Theranostics has
the spotlight because it's delivering on a promise we've been chasing for years in cancer care, truly personalized
targeted treatment with fewer side effects than traditional options.
Guests:
Lindsay Williams, MBA, CNMT, R.T.(N)(CT)(ARRT)
Pharmacy Sourcing Portfolio Executive
Vizient
Setu Shah, MPH
Sr. Associate, Intelligence
Sg2
Janna Laton, MBA, CNMT, NMTCB(CT), R.T.(R)(N)(MR)(ARRT)
Independent Contributor and SME
Host:
Adam Fairbourn, MBA, CNMT
Senior Director, Contract Services
Vizient, Capital Equipment Solutions
Show Notes:
[00:45] Defining Theranostics and why it’s getting attention
[02:10] “See what you treat and treat what you see” captures the power of Theranostics
[03:10] Why neuroendocrine tumors and prostate cancer are particularly well suited for this approach
[03:50] Prostate specific membrane antigen or PSMA targeted imaging and treatment work and results
[05:28] How Theranostics compares with more traditional cancer treatments in terms of precision and side effects
Links | Resources:
Subscribe Today!
Apple Podcasts
Spotify
YouTube
RSS Feed